1-2 of 2
Stephanie Barath
Close
Save search
Sort by
Journal Articles

A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients

Free
Sonia Christian, MD, Kelley E. Kozma, DO, Stephanie Barath, Ardaman Shergill, MD, Damiano Rondelli, MD, David Peace, MD, Santosh L. Saraf, MD, Annie Lee Oh, MD, Karen Sweiss, PharmD, Irum Khan, MBBS, Pritesh Patel, MD, Arkadiusz Dudek, MD PhD, John G. Quigley
Journal: Blood
Blood (2018) 132 (Supplement 1): 5218.
https://doi.org/10.1182/blood-2018-99-111412
Published: 2018
Journal Articles

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase a, in Myelofibrosis

Free
Naseema Gangat, MBBS, Ronan T. Swords, MD PhD FRCPI, FRCPath, Brady Lee Stein, MDMHS, Christian Marinaccio, Justin M Watts, MD, Olga Frankfurt, MD, Jessica K. Altman, MD, Aref Al-Kali, MD, Darci Zblewski, CNP, Sandeep Gurbuxani, Jeremy Q. Wen, MD PhD, Roberto Tapia, BS, Stephanie Barath, Amy Graf, Amy Handlogten, Yvonne Trang Dinh, BS, Kristen Englund, Shradha Patel, Orlando Bodes, Jillian Ogden, Francis J. Giles, MD MB, FRCPath, Ayalew Tefferi, MD, John D. Crispino, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1631.
https://doi.org/10.1182/blood.V130.Suppl_1.1631.1631
Published: 2017